Fresenius and WuXi Biologics have entered an exclusive development agreement that gives Fresenius options on up to 37 potential biosimilar candidates over the next decade. The Fresenius WuXi biosimilar deal could broaden the German healthcare group’s pipeline, but each candidate remains subject to selection and development.
What the Fresenius WuXi biosimilar deal includes
Announced on 2 November 2026, the agreement covers up to 37 identified candidates. Fresenius says its portfolio of marketed and pipeline molecules could grow from 29 to as many as 66 over the next decade. The company says the candidates relate to originator medicines with combined sales above €370 billion. That figure describes sales associated with the reference medicines; it is not a revenue forecast for the biosimilars or the partners.
The potential portfolio spans 13 therapeutic areas and several biologic formats, including monoclonal and bispecific antibodies, antibody-drug conjugates and fusion proteins. Fresenius expects initial development to focus on polatuzumab vedotin and teprotumumab. These are proposed development priorities, not newly approved biosimilars.
How candidate selection and rights are structured
Under the Fresenius WuXi biosimilar deal, Fresenius will select candidates using its stated criteria for market attractiveness, development risk and expected returns. It will pay WuXi Biologics on a fee-for-service basis for each candidate it chooses to develop. Fresenius says it will hold exclusive global commercialisation rights, including marketing authorisations, for products developed under the agreement.
The partners also leave manufacturing decisions open for each programme. Fresenius may consider transferring selected products to its mAbxience network, but the announcement does not confirm that any transfer will occur.
What the Fresenius WuXi biosimilar deal could mean for the sector
The deal gives Fresenius access to a wider set of potential development projects while allowing it to choose which programmes proceed. In principle, a broader pipeline can spread development opportunities across products and therapeutic areas. The agreement alone does not establish that candidates will succeed in development, receive regulatory approval, launch, or improve patient access.
What to watch as the Fresenius WuXi biosimilar deal develops
- Which candidates Fresenius selects and when development programmes begin.
- Clinical, analytical and regulatory milestones for the initial programmes.
- Any decisions about manufacturing strategy, including possible use of mAbxience.
- Whether Fresenius provides further details on timelines, investment or candidate-specific plans.
This article summarises a corporate announcement for industry awareness. The number of candidates, pipeline expansion and future commercial opportunities remain subject to decisions and development outcomes.
Sources
Fresenius company announcement via PR Newswire (2 November 2026) · Reuters: Fresenius signs biosimilars pipeline agreement with WuXi Biologics (2 November 2026).
